Graduate Programme in Biomedical Sciences, Faculty of Allied Health Sciences, Thammasat University, Rangsit Campus, Thailand.
Department of Medical Technology, Faculty of Allied Health Sciences, Thammasat University, Rangsit Campus, Thailand.
Blood Transfus. 2020 Sep;18(5):366-373. doi: 10.2450/2020.0031-20. Epub 2020 Jul 22.
Alloanti-Di can be implicated in mild to severe blood transfusion reactions. Given the concomitance of a high prevalence of the Di antigen and antibody circulating in some populations, an anti-Di typing reagent is required in order to enable safe blood transfusions. Limitations of hybridoma technology to produce such a reagent led to the use of phage display technology to generate an anti-Di monoclonal antibody.
A library of phages displaying murine single-chain variable fragment antibody (scFv-phages) was consecutively adsorbed with different panels of Di(a-b+) red cells to eliminate scFc-phages that potentially bind irrelevant blood group antigens. Thereafter, the subtractive library was specifically selected for the scFv-phages that bound Di antigen by sequentially biopanning the library with Di(a+b+) cell ghosts and Di(a+b-) intact red cells. A specific interaction between the selected scFv-phages and Di epitope was validated with the Di peptide by a competitive haemagglutination inhibition assay and confirmed with the red cells by flow cytometry.
An scFv-phage clone specifically bound the Di epitope, as shown by its binding competition with the human anti-Di to the Di peptide in a haemagglutination inhibition test. Moreover, it was highly reactive to Di(a+b+) red cells but not to Di(a-b+) red cells, as determined by flow cytometry.
In this study, a Di-specific scFv-phage antibody was successfully produced. The selection protocol might be a prototypic platform for producing monoclonal antibodies to relevant blood group antigens. The scFv-phage produced in this way warrants further development for use as a reagent for Di red cell typing.
同种异体抗-Di 可引起轻度至重度输血反应。鉴于某些人群中 Di 抗原和抗体的高流行率,需要使用抗-Di 定型试剂,以便进行安全输血。杂交瘤技术生产此类试剂存在局限性,因此使用噬菌体展示技术来产生抗-Di 单克隆抗体。
连续用不同的 Di(a-b+)红细胞面板吸附噬菌体展示的鼠单链可变片段抗体 (scFv-phages) 文库,以消除可能与无关血型抗原结合的 scFc-phages。此后,通过用 Di(a+b+)细胞胞 ghosts 和 Di(a+b-)完整红细胞依次对文库进行生物淘选,对具有 Di 抗原结合能力的 scFv-phages 进行选择。通过竞争性血凝抑制试验,用 Di 肽验证所选 scFv-phages 与 Di 表位之间的特异性相互作用,并通过流式细胞术用红细胞进行确认。
噬菌体 scFv 克隆与 Di 表位特异性结合,这表现在其与人类抗-Di 对 Di 肽的血凝抑制试验中的竞争结合。此外,它对 Di(a+b+)红细胞高度反应,但对 Di(a-b+)红细胞不反应,这通过流式细胞术确定。
在这项研究中,成功地产生了抗-Di 特异性 scFv 噬菌体抗体。选择方案可能是生产相关血型抗原单克隆抗体的原型平台。通过这种方式产生的 scFv-phage 值得进一步开发,用作 Di 红细胞定型试剂。